Ki-67 algorithm from Zeno Pathology in clinical study
zeno pathology

Together with Stacey Joosten et al. from the Netherlands Cancer Institute, WSK Medical collaborated on the clinical study “IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women”.

In this study, we compared pathologist assessed IHC-based Ki67 in samples from pre- and postmenopausal women in a neo-adjuvant, endocrine therapy focused trial and compared these results – among others – with our Artificial Intelligence (AI) Ki-67 algorithm that is part of our CE certified digital pathology solution Zeno Pathology.

The results from this study showed the added value of using AI in collaboration with doctors to assist in decision-making and analysis of complex, clinical data. The paper can be found here.

Related posts

Guest lecture Zeno AI – 24th of February 2023 – Online

Guest lecture Zeno AI – 24th of February 2023 – Online

WSK Medical won the Dutch Applied AI Award at the beginning of October 2022 and is now coming to the Amsterdam University of Applied Sciences for a great guest lecture about their application Zeno AI. Zeno AI helps ENT doctors to detect throat cancer at an early...

read more